RBC Capital Markets' Michael Yee said the selloff of Puma Biotech is in an overreaction and that the stock will represents an opportunity in the long run.» Read More
Color Genomics plans to charge only $249 for an analysis of cancer-risk genes. New York Times reports.
Changes in the prescription drug market may have curbed prescription opioid abuse but may have also fueled a rise in heroin use.
Drugmaker Teva is considering making a bid for Mylan, but has not yet made a decision on an offer, Dow Jones reported.
CNBC's Meg Tirrell provides insight to a report on Teva Pharmaceutical Industries Ltd. exploring a takeover offer from Mylan.
Biotech investors are going to be busy with new data on Alzheimer's drugs, cancer and genetic disorders on the way. Here's what analysts are watching.
For Pfizer and Merck, two big names that have ridden the merger wave, buying up more business is a possibility, their CEOs said.
Discussing the growth in the biotech industry, and current trading action, with Nasdaq OMX CEO Robert Greifeld.
After an abrupt departure, Former Teva CEO Jeremy Levin is now leading a start-up focused on rare neurological disorders.
Is it the golden age for cancer research Stephen Isaacs, Aduro Biotech CEO, discusses some of the advances in medicine of late.
Australia is making it harder for parents to file personal objections against vaccination.
Johnson & Johnson reports quarterly earnings that beat expectations despite a 7.2 percent drag on the strong dollar.
It can cost $75,000 to $250,000, and the names keep getting stranger as companies balance regulator concerns with the desire to market the product.
CNBC "Fast Money" traders discussed how to trade big names in the surging but uncertain biotechnology sector.
The "Halftime Report" traders give their trades for the second half.
Barbara Ryan, Clermont Partners, discusses pharmaceutical consolidation including acquisitions and how to be a top player in the pharma sector.
Perrigo shares shot higher after news that Mylan proposed to buy Perrigo for $205 per share.
Eric Schmidt, senior research analyst at Cowen & Co, explains why despite the outperformance in the biotech sector, there's more room to run.
An estimated 3 million Americans have autism. But what exactly what is it, and where are we on treatments?
An intestinal illness called Shigellosis and carried by international travelers is spreading across the U.S., according to the Centers for Disease Control and Prevention.
CNBC's Meg Tirrell takes a deeper look at Autism, the people it affects and where treatment stands.
Get the best of CNBC in your inbox